Visium Asset Management, managed by Jacob Gottlieb, has disclosed a new position in Quotient Ltd (NASDAQ:QTNT). A new filing with the U.S. Securities and Exchange Commission showed that the fund now owns 745,671 shares of the company, representing 5.1 % of common stock. The stake is passive by nature.
Quotient Ltd (NASDAQ:QTNT) is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests for blood grouping and serological disease screening. The company recently conducted its initial public offering of 5 million units, each consisting of one ordinary share and one warrant to purchase 0.8 of one ordinary share, at a price of $8.00 per unit, according to a news release.
In a Form 8-K filed at the end of May with the SEC, Quotient Ltd (NASDAQ:QTNT) said that it entered into a warrant agent agreement with Continental Stock Transfer & Trust Co. in connection with its IPO.
For the fourth fiscal quarter ended March 31, 2014, Quotient Ltd (NASDAQ:QTNT) reported a net loss attributable to ordinary shareholders of $5.2 million, or a loss of $16.15 per ordinary share, compared with $1.7 million, or a loss of $22.02 per ordinary share in the same quarter in 2013. On a full-year basis, the company posted a net loss attributable to ordinary shareholders of $10.2 million, or a loss of $54.41 per ordinary share, compared with $4.7 million, or a loss of $62.97 per ordinary share in fiscal year 2013.
Visium Asset Management was founded by Jacob Gottlieb in 2005. The fund initially specialized in health care stocks and now manages more than $3.5 billion in its broader range of holdings. At the end of April, Visium Asset Management reported upping its stake in Brookdale Senior Living Inc. (NYSE:BKD), adding 2.29 million shares to 6.31 million shares. In addition, Visium Asset Management initiated a 1.6 million position in AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) in the beginning of March.